DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02344641

UnknownPhase NA

Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

Asset

Exenatide

GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

234

estimated

Study population

Heart failure, Type 2 diabetes

Key I/E criteria

•HbA1c 7-10%•EF ≤40%

Primary endpoint

•NT-proBNP, change

Identifiers

Registered as

NCT IDNCT02344641
Org study IDISSEXEN0054

Timeline

Milestones

Study first posted2015-01-26estimated
Last update posted2015-01-27estimated
Study start2015-01 (month precision)
Primary completion2016-12estimated (month precision)
Study completion2016-12estimated (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Heart failureType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Diagnosed Type 2 diabetes mellitus

2. HbA1c 7%-10% and Fasting plasma glucose(FBG) <10mmol/L

3. Age 18-65 years

4. NT-proBNP level≥ 450 pg/ml

5. Left ventricular ejection fraction (LVEF)<40%

Exclusion criteria

1. Uncorrected primary vascular disease

2. congenital heart disease

3. Left ventricular outflow obstruction

4. Myocarditis

5. Aneurysm

6. uncontrolled severe arrhythmia

7. cardiogenic shock

8. unstable angina, or acute myocardial infarction

9. Severe primary hepatic, renal, or hematologic disease

10. Cr>194.5 mmol/l or K+>5.5 mmol/l

11. Systolic blood pressure (SBP) ≥180mm Hg or diastolic blood pressure (DBP) ≥110mm Hg

12. Alanine aminotransferase (ALT) >3 times the upper normal limit

13. Patients were likely to undergo coronary artery bypass graft surgery during the following 4 weeks

14. Patients had undergone or were likely to undergo cardiac resynchronization therapy

15. Pregnant or lactating known

16. Suspected to be allergic to the study drugs

17. Use dipeptidyl peptidase-4 (DPP-4) or glucagon-like peptide-1 (GLP-1) drug in 3 months

18. Hyperthyroidism and Hypothyroidism

19. Tumor

20. Received another investigational drug within 30 days prior to randomization

21. Severe mental health condition or other uncontrolled systemic disease.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Heart failure

1 endpoint
Primary/protocol endpoint

The change in plasma NT-proBNP level after using exenatide for 4 weeks

Time frame:4 weeks

NT-proBNP, change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.